Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
McKinsey
Boehringer Ingelheim
AstraZeneca
Medtronic

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PRAZOSIN HYDROCHLORIDE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

505(b)(2) Clinical Trials for Prazosin Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00487032 Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation Completed Brian J Lipworth Phase 4 2008-05-01 The investigators wish to evaluate the onset of tolerance to nasal decongestants like oxymetazoline (available over the counter) and the mechanism of tolerance particularly with differential effects on alpha 1 and alpha 2 adrenoreceptors on the nose. The investigators will 'tease' out by using an alpha 1 blocker called Prazosin. The investigators hypothesize that alpha 1 receptors mediate arterial constriction and this will be captured by measuring nasal blood flow. The investigators also hypothesize that alpha 2 receptors mediate venous sinusoid constriction and this the investigators will capture by airflow parameters like Peak Nasal Inspiratory Flow, Rhinomanometry, Oscillometric indices etc.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Prazosin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00007592 Hypertension Screening and Treatment Program Completed VA Office of Research and Development N/A 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00108420 Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance Completed VA Office of Research and Development Phase 4 2003-10-01 The purpose of this study is to determine whether prazosin will reduce the incidence of nightmares, sleep disturbance, and overall symptoms in combat trauma-exposed individuals with PTSD.
NCT00148837 Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis Unknown status French National Agency for Research on AIDS and Viral Hepatitis Phase 2 2004-09-01 Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosis regress, in patients with chronic hepatitis C and severe fibrosis.
NCT00161473 Alzheimer's in Long-Term Care--Treatment for Agitation Completed National Institute on Aging (NIA) N/A 2001-01-01 The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease (AD) and other types of dementia in late life.
NCT00161473 Alzheimer's in Long-Term Care--Treatment for Agitation Completed University of Washington N/A 2001-01-01 The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease (AD) and other types of dementia in late life.
NCT00167687 Prazosin Alcohol Dependence IVR Study Completed VA Office of Research and Development Phase 4 2005-09-01 This double-blind placebo controlled pilot trial will test the hypothesis that prazosin, an alpha-1 adrenergic receptor antagonist, reduced alcohol consumption and alcohol craving in alcohol dependent individuals without Post Traumatic Stress Disorder (PTSD). The intervention period is six weeks.
NCT00167687 Prazosin Alcohol Dependence IVR Study Completed University of Washington Phase 4 2005-09-01 This double-blind placebo controlled pilot trial will test the hypothesis that prazosin, an alpha-1 adrenergic receptor antagonist, reduced alcohol consumption and alcohol craving in alcohol dependent individuals without Post Traumatic Stress Disorder (PTSD). The intervention period is six weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Prazosin Hydrochloride

Condition Name

Condition Name for Prazosin Hydrochloride
Intervention Trials
Stress Disorders, Post-Traumatic 7
Posttraumatic Stress Disorder 5
Alcoholism 4
PTSD 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Prazosin Hydrochloride
Intervention Trials
Stress Disorders, Post-Traumatic 18
Disease 15
Stress Disorders, Traumatic 13
Alcoholism 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Prazosin Hydrochloride

Trials by Country

Trials by Country for Prazosin Hydrochloride
Location Trials
United States 82
Canada 5
France 2
United Kingdom 2
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Prazosin Hydrochloride
Location Trials
Washington 21
California 6
Connecticut 4
Georgia 4
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Prazosin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Prazosin Hydrochloride
Clinical Trial Phase Trials
Phase 4 8
Phase 3 5
Phase 2 13
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Prazosin Hydrochloride
Clinical Trial Phase Trials
Recruiting 18
Completed 17
Unknown status 8
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Prazosin Hydrochloride

Sponsor Name

Sponsor Name for Prazosin Hydrochloride
Sponsor Trials
VA Office of Research and Development 11
VA Puget Sound Health Care System 9
Seattle Institute for Biomedical and Clinical Research 9
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Prazosin Hydrochloride
Sponsor Trials
Other 50
U.S. Fed 27
NIH 15
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Moodys
Mallinckrodt
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.